Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
3.
Neurobiol Learn Mem ; 155: 379-389, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30195050

RESUMO

Viral infection during early stage of life influences brain development and results in several neurodevelopmental disorders such as schizophrenia, autism and behavioral abnormalities. However, the mechanism through which infection causes long-term behavioral defects is not well known. To elucidate this, we have used synthetic polyinosinic-polycytidylic acid [poly (I:C)] which acts as a dsRNA molecule and interacts with toll-like receptor-3 (TLR-3) of microglia cells to evoke the immune system, thus mimicking the viral infection. Rat pups of postnatal day (PND) 7 were infused with a single dose of poly (I:C) (5 mg/kg BW) and vehicle alone to controls. When these pups grew to 3, 6 and 12 weeks, their spatial and fear conditioning memory were impaired as assessed by Morris water maze and passive avoidance test, respectively. We checked the immune activation by staining of TNF-α in the hippocampus and observed that poly (I:C) exposure elevated the number of TNF-α positive cells immediately after 12 h of infusion in one week rat and it persisted up to postnatal age of 3 and 12 weeks. Moreover, poly (I:C) significantly decreased the binding of 3H-QNB to the cholinergic receptors in the frontal cortex and hippocampus of 3 and 6 weeks rats as compared to control but did not change significantly in 12 weeks rats. RT-PCR and immunoblotting results showed that poly (I:C) exposure upregulated the expression of memory associated genes (BDNF, Arc, EGR1) at mRNA and protein level in frontal cortex and hippocampus of 3 weeks rats as compared to control. However, long-time persistence of poly (I:C) effects significantly decreased the expression of these genes in both brain regions of 12 weeks rats. Taken together, it is evident that early life exposure to poly (I:C) has a long-term effect and impairs learning and memory, probably through TNF-α mediated neuroinflammation and alteration in the expression of memory associated genes in frontal cortex and hippocampus of rats.


Assuntos
Encéfalo/crescimento & desenvolvimento , Encéfalo/imunologia , Memória/fisiologia , Plasticidade Neuronal/genética , Plasticidade Neuronal/imunologia , Aprendizagem Espacial/fisiologia , Animais , Encéfalo/efeitos dos fármacos , Condicionamento Clássico/efeitos dos fármacos , Condicionamento Clássico/fisiologia , Feminino , Lobo Frontal/efeitos dos fármacos , Lobo Frontal/imunologia , Expressão Gênica , Hipocampo/efeitos dos fármacos , Hipocampo/imunologia , Masculino , Memória/efeitos dos fármacos , Plasticidade Neuronal/efeitos dos fármacos , Poli I-C/administração & dosagem , Ratos Wistar , Receptores Muscarínicos/metabolismo , Aprendizagem Espacial/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismo
4.
Sci Rep ; 6: 28142, 2016 06 23.
Artigo em Inglês | MEDLINE | ID: mdl-27334554

RESUMO

The plethora of literature has supported the potential benefits of Resveratrol (RV) as a life-extending as well as an anticancer compound. However, these two functional discrepancies resulted at different concentration ranges. Likewise, the role of Resveratrol on adult neurogenesis still remains controversial and less understood despite its well documented health benefits. To gather insight into the biological effects of RV on neurogenesis, we evaluated the possible effects of the compound on the proliferation and survival of neural progenitor cells (NPCs) in culture, and in the hippocampus of aged rats. Resveratrol exerted biphasic effects on NPCs; low concentrations (10 µM) stimulated cell proliferation mediated by increased phosphorylation of extracellular signal-regulated kinases (ERKs) and p38 kinases, whereas high concentrations (>20 µM) exhibited inhibitory effects. Administration of Resveratrol (20 mg/kg body weight) to adult rats significantly increased the number of newly generated cells in the hippocampus, with upregulation of p-CREB and SIRT1 proteins implicated in neuronal survival and lifespan extension respectively. We have successfully demonstrated that Resveratrol exhibits dose dependent discrepancies and at a lower concentration can have a positive impact on the proliferation, survival of NPCs and aged rat hippocampal neurogenesis implicating its potential as a candidate for restorative therapies against age related disorders.


Assuntos
Envelhecimento/efeitos dos fármacos , Células-Tronco Neurais/citologia , Neurogênese/efeitos dos fármacos , Estilbenos/administração & dosagem , Células A549 , Envelhecimento/metabolismo , Animais , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/metabolismo , Relação Dose-Resposta a Droga , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Humanos , Células-Tronco Neurais/efeitos dos fármacos , Células-Tronco Neurais/metabolismo , Fosforilação/efeitos dos fármacos , Ratos , Resveratrol , Sirtuína 1/metabolismo , Estilbenos/farmacologia
5.
Sci Rep ; 5: 14038, 2015 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-26370177

RESUMO

We demonstrate the role of molecular switching of TrkA/p75(NTR) signaling cascade in organophosphate pesticide-Monocrotophos (MCP) induced neurotoxicity in stem cell derived cholinergic neurons and in rat brain. Our in-silico studies reveal that MCP followed the similar pattern of binding as staurosporine and AG-879 (known inhibitors of TrkA) with TrkA protein (PDB ID: 4AOJ) at the ATP binding sites. This binding of MCP to TrkA led to the conformational change in this protein and triggers the cell death cascades. The in-silico findings are validated by observing the down regulated levels of phosphorylated TrkA and its downstream molecules viz., pERK1/2, pAkt and pCREB in MCP-exposed cells. We observe that these MCP induced alterations in pTrkA and downstream signaling molecules are found to be associated with apoptosis and injury to neurons. The down-regulation of TrkA could be linked to increased p75(NTR). The in-vitro studies could be correlated in the rat model. The switching of TrkA/p75(NTR) signaling plays a central role in MCP-induced neural injury in rBNSCs and behavioral changes in exposed rats. Our studies significantly advance the understanding of the switching of TrkA/p75(NTR) that may pave the way for the application of TrkA inducer/p75(NTR) inhibitor for potential therapeutic intervention in various neurodegenerative disorders.


Assuntos
Inibidores da Colinesterase/farmacologia , Inseticidas/farmacologia , Monocrotofós/farmacologia , Receptor trkA/metabolismo , Receptores de Fator de Crescimento Neural/metabolismo , Transdução de Sinais/efeitos dos fármacos , Animais , Apoptose/efeitos dos fármacos , Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Diferenciação Celular/efeitos dos fármacos , Células Cultivadas , Inibidores da Colinesterase/química , Inibidores da Colinesterase/toxicidade , Inseticidas/química , Inseticidas/toxicidade , Modelos Moleculares , Conformação Molecular , Simulação de Acoplamento Molecular , Monocrotofós/química , Monocrotofós/toxicidade , Proteínas do Tecido Nervoso , Células-Tronco Neurais/citologia , Células-Tronco Neurais/efeitos dos fármacos , Células-Tronco Neurais/metabolismo , Neurônios/citologia , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Ratos , Receptor trkA/antagonistas & inibidores , Receptor trkA/química , Receptores de Fatores de Crescimento , Relação Estrutura-Atividade
6.
ACS Nano ; 9(5): 4850-71, 2015 May 26.
Artigo em Inglês | MEDLINE | ID: mdl-25825926

RESUMO

Sustained and safe delivery of dopamine across the blood brain barrier (BBB) is a major hurdle for successful therapy in Parkinson's disease (PD), a neurodegenerative disorder. Therefore, in the present study we designed neurotransmitter dopamine-loaded PLGA nanoparticles (DA NPs) to deliver dopamine to the brain. These nanoparticles slowly and constantly released dopamine, showed reduced clearance of dopamine in plasma, reduced quinone adduct formation, and decreased dopamine autoxidation. DA NPs were internalized in dopaminergic SH-SY5Y cells and dopaminergic neurons in the substantia nigra and striatum, regions affected in PD. Treatment with DA NPs did not cause reduction in cell viability and morphological deterioration in SH-SY5Y, as compared to bulk dopamine-treated cells, which showed reduced viability. Herein, we report that these NPs were able to cross the BBB and capillary endothelium in the striatum and substantia nigra in a 6-hydroxydopamine (6-OHDA)-induced rat model of PD. Systemic intravenous administration of DA NPs caused significantly increased levels of dopamine and its metabolites and reduced dopamine-D2 receptor supersensitivity in the striatum of parkinsonian rats. Further, DA NPs significantly recovered neurobehavioral abnormalities in 6-OHDA-induced parkinsonian rats. Dopamine delivered through NPs did not cause additional generation of ROS, dopaminergic neuron degeneration, and ultrastructural changes in the striatum and substantia nigra as compared to 6-OHDA-lesioned rats. Interestingly, dopamine delivery through nanoformulation neither caused alterations in the heart rate and blood pressure nor showed any abrupt pathological change in the brain and other peripheral organs. These results suggest that NPs delivered dopamine into the brain, reduced dopamine autoxidation-mediated toxicity, and ultimately reversed neurochemical and neurobehavioral deficits in parkinsonian rats.


Assuntos
Barreira Hematoencefálica/metabolismo , Dopamina/química , Dopamina/metabolismo , Nanopartículas/química , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/fisiopatologia , Animais , Linhagem Celular Tumoral , Dopamina/efeitos adversos , Neurônios Dopaminérgicos/metabolismo , Portadores de Fármacos/efeitos adversos , Portadores de Fármacos/química , Portadores de Fármacos/metabolismo , Liberação Controlada de Fármacos , Humanos , Ácido Láctico/química , Neostriado/efeitos dos fármacos , Neostriado/metabolismo , Oxirredução , Oxidopamina/química , Oxidopamina/farmacologia , Oxidopamina/uso terapêutico , Doença de Parkinson/metabolismo , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Ratos , Ratos Wistar , Receptores Dopaminérgicos/metabolismo , Segurança , Regulação para Cima/efeitos dos fármacos
7.
Fitoterapia ; 83(6): 1092-9, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22579842

RESUMO

This study was undertaken to ascertain the antipsychotic properties of Rauwolfia tetraphylla L. leaves and to isolate and characterize the antipsychotic constituents. Among the MeOH extract and some alkaloidal fractions at different pHs, the alkaloidal CHCl(3) fraction at pH-9 (2C) showed the highest antipsychotic activity against dopaminergic (DA-D(2)) and serotonergic (5-HT(2A)) receptors in-vitro and amphetamine induced hyperactive mouse model in-vivo. The activity guided isolation of CHCl(3) fraction (2C) afforded six indole alkaloids: 10-methoxytetrahydroalstonine (1), isoreserpiline (2), an isomeric mixture of 11-demethoxyreserpiline (3) and 10-demethoxyreserpiline (4), α-yohimbine (5) and reserpiline (6). Given orally, alkaloids 3-6 showed significant antipsychotic activity in a dose dependent manner. None of the extract, alkaloidal fractions or alkaloids showed any extra pyramidal symptoms at the tested doses. It was also observed that MeOH extract was behaving similar to other clinically used novel atypical antipsychotics in having 5-HT(2A) occupancy greater than the DA-D(2) receptor at the tested doses. Further toxicity and safety evaluation studies of MeOH extracts of R. tetraphylla leaves at different doses (10, 100, 300 and 2000 mg/kg) on female Swiss albino mice showed that MeOH extract is non toxic. The isolated alkaloids, 3-6 could serve as a promising lead structure for drug development of treating psychotic conditions in human.


Assuntos
Antipsicóticos/uso terapêutico , Hipercinese/tratamento farmacológico , Alcaloides Indólicos/uso terapêutico , Fitoterapia , Extratos Vegetais/uso terapêutico , Rauwolfia/química , Receptores de Amina Biogênica/metabolismo , Anfetamina , Animais , Antipsicóticos/isolamento & purificação , Antipsicóticos/farmacologia , Relação Dose-Resposta a Droga , Feminino , Concentração de Íons de Hidrogênio , Hipercinese/induzido quimicamente , Hipercinese/metabolismo , Alcaloides Indólicos/química , Alcaloides Indólicos/farmacologia , Camundongos , Camundongos Endogâmicos , Neurotransmissores/isolamento & purificação , Neurotransmissores/farmacologia , Neurotransmissores/uso terapêutico , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Folhas de Planta/química , Receptores Dopaminérgicos/metabolismo , Receptores de Serotonina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...